Biotest AG 是一家总部位于德国的生物技术公司,公司总部位于黑森州德赖艾希,在职员工2,495人。该公司是德国领先的血浆蛋白和生物药物供应商,业务链涵盖从临床前和临床开发到全球市场推广与分销,主要专注于临床免疫学、血液学和重症监护医学领域。公司研发、生产和销售基于人血浆的免疫球蛋白、凝血因子和白蛋白,用于治疗免疫系统和造血系统疾病。此外,公司还利用重组技术开发针对浆细胞癌和系统性红斑狼疮适应症的单克隆抗体。
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for BIESF. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: BIESF is a Sell candidate.
BIESF stock price ended at $32 on 星期一, after dropping NaN%
On the latest trading day Mar 10, 2025, the stock price of BIESF fell by NaN%, dropping from $32.00 to $32.00. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $32.00 and a high of $32.00. On the latest trading day, the trading volume for BIESF decreased by -- shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 100 shares were traded, with a market value of approximately $633.1M.